Intellia Therapeutics (NTLA) Invested Capital (2016 - 2025)
Historic Invested Capital for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $748.4 million.
- Intellia Therapeutics' Invested Capital fell 2225.12% to $748.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $748.4 million, marking a year-over-year decrease of 2225.12%. This contributed to the annual value of $872.0 million for FY2024, which is 1696.99% down from last year.
- Per Intellia Therapeutics' latest filing, its Invested Capital stood at $748.4 million for Q3 2025, which was down 2225.12% from $715.3 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Invested Capital registered a high of $1.2 billion during Q4 2022, and its lowest value of $494.8 million during Q2 2021.
- In the last 5 years, Intellia Therapeutics' Invested Capital had a median value of $962.6 million in 2024 and averaged $923.8 million.
- As far as peak fluctuations go, Intellia Therapeutics' Invested Capital soared by 23587.1% in 2021, and later tumbled by 2634.3% in 2025.
- Intellia Therapeutics' Invested Capital (Quarter) stood at $1.0 billion in 2021, then increased by 18.78% to $1.2 billion in 2022, then fell by 15.01% to $1.1 billion in 2023, then decreased by 16.97% to $872.0 million in 2024, then decreased by 14.17% to $748.4 million in 2025.
- Its Invested Capital was $748.4 million in Q3 2025, compared to $715.3 million in Q2 2025 and $779.9 million in Q1 2025.